Skip to content
Screener

Stoke Therapeutics, Inc. STOK Q3 2025 earnings

Reported November 4, 2025 · After market close

Revenue$10.6MBeat by $6.1M
EPS-$0.65Miss by $0.11
Revenue estimate$4.6M
EPS estimate-$0.54

Next report

Nov 3, 2026 (in 2 months)
Revenue estimate$8.2M
EPS estimate-$0.88

Financials

Q3 2025

Income statement

See full
Revenue$10.6M+117%
Operating income-$43.1M-43.6%
Net income-$38.3M-45.1%
EPS (diluted)-$0.65-38.3%

Balance sheet

See full
Cash & equivalents$83.4M-44.4%
Total debt$1.8M-66.1%
Total equity$308.1M+32.7%
Total assets$360.3M+22.8%

Cash flow

See full
CapEx$132.0K+28.2%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$1.29B+87.9%
Enterprise value$1.21B+123%
P/E31.7×—
P/S6.3×-34.7×

Profitability

See full
Operating margin13.2%+6.7pp
Net margin19.7%+10.0pp

Returns & leverage

See full
Return on equity15%+8.5pp
Debt / equity0×0.0×
Current ratio6.5×+1.4×

FAQ

When did Stoke Therapeutics, Inc. report Q3 2025 earnings?
Stoke Therapeutics, Inc. (STOK) reported Q3 2025 earnings on November 4, 2025 after market close.
What were Stoke Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Stoke Therapeutics, Inc. reported revenue of $10.6M and eps of $-0.65 for Q3 2025.
Did Stoke Therapeutics, Inc. beat estimates in Q3 2025?
Revenue beat the consensus estimate of $4.6M by $6.1M. EPS missed the consensus estimate of $-0.54 by $0.11.
How did Stoke Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 117.2% from $4.9M a year earlier and eps declined 38.3% from $-0.47.
Where can I find Stoke Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-264644) and the 10-Q periodic report (0001193125-25-264720) directly on SEC EDGAR. The filing index links above go to sec.gov.